Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of PEG-IFN alfa-2a BA-free vs Market Formulation in Healthy Chinese Subjects
NCT02573025Phase 1Completed
- Sponsor
- Roche
- Start
- Sep 2015
- Primary completion
- Apr 2016
- Modality
- rProtein (Recombinant Protein), Biologic
- Countries
- 5
01
Overview
Phase 1, randomised, open-label trial of peginterferon alfa-2a in hepatitis B (HBV) and hepatitis C (HCV) (2 arms), sponsored by Roche. Primary endpoints: Maximum Observed Concentration and Area Under the Concentration-Time Curve From Time Zero to 816 hours. Started Sep 2015; status: completed.
02
Drugs
peginterferon alfa-2a
03
Conditions
hepatitis B (HBV)hepatitis C (HCV)
Beyond the preview
Go deeper on NCT02573025.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02573025.